CLINICAL TRIALS PROFILE FOR TREOSULFAN

Clinical Trials for Treosulfan

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00129155 ↗	MiniMUD Study - Unrelated Reduced Intensity Conditioning With Treosulfan® for Allogeneic Stem Cell Transplantation in Patients With Hematological Malignancies	Unknown status	Hospices Civils de Lyon	Phase 2	In this study, treosulfan is evaluated for conditioning in allogenic stem cell transplantation. The procedure and the follow-up are the same as in standard allogenic transplant. The donor is unrelated (identical HLA). The graft is haematological peripheral blood stem cell. The conditioning with reduced intensity is: fludarabine (from day -6 to day -2), treosulfan (from day -6 to day -4) and thymoglobuline (from day -2 to day -1).
NCT00168870 ↗	Study of Metastatic Ocular Melanoma	Unknown status	Charite University, Berlin, Germany	Phase 2	This study evaluates treatment with combination versus monotherapy for patients with metastatic ocular melanoma.
NCT00170690 ↗	Preference Study With Elderly Patients Recurrent Ovarian Cancer	Completed	North Eastern German Society of Gynaecological Oncology	Phase 3	Comparison of the patient compliance treosulfan oral vs. intravenous (defined as end of therapy for the patient)
NCT00170690 ↗	Preference Study With Elderly Patients Recurrent Ovarian Cancer	Completed	North Eastern Germany Society of Gynaecologic Oncology	Phase 3	Comparison of the patient compliance treosulfan oral vs. intravenous (defined as end of therapy for the patient)
NCT00253513 ↗	Treosulfan and Fludarabine in Treating Younger Patients Who Are Undergoing a Donor Stem Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome	Completed	medac GmbH	Phase 1/Phase 2	RATIONALE: Drugs used in chemotherapy, such as treosulfan and fludarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving treosulfan and fludarabine together with a donor bone marrow transplant or a peripheral stem cell transplant may be an effective treatment for acute myeloid leukemia, acute lymphoblastic leukemia, or myelodysplastic syndrome. PURPOSE: This phase II trial is studying giving treosulfan together with fludarabine to see how well it works in treating patients who are undergoing a donor stem cell transplant for acute myeloid leukemia, acute lymphoblastic leukemia, or myelodysplastic syndrome.
NCT00253513 ↗	Treosulfan and Fludarabine in Treating Younger Patients Who Are Undergoing a Donor Stem Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome	Completed	National Cancer Institute (NCI)	Phase 1/Phase 2	RATIONALE: Drugs used in chemotherapy, such as treosulfan and fludarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving treosulfan and fludarabine together with a donor bone marrow transplant or a peripheral stem cell transplant may be an effective treatment for acute myeloid leukemia, acute lymphoblastic leukemia, or myelodysplastic syndrome. PURPOSE: This phase II trial is studying giving treosulfan together with fludarabine to see how well it works in treating patients who are undergoing a donor stem cell transplant for acute myeloid leukemia, acute lymphoblastic leukemia, or myelodysplastic syndrome.
NCT00253513 ↗	Treosulfan and Fludarabine in Treating Younger Patients Who Are Undergoing a Donor Stem Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome	Completed	OHSU Knight Cancer Institute	Phase 1/Phase 2	RATIONALE: Drugs used in chemotherapy, such as treosulfan and fludarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving treosulfan and fludarabine together with a donor bone marrow transplant or a peripheral stem cell transplant may be an effective treatment for acute myeloid leukemia, acute lymphoblastic leukemia, or myelodysplastic syndrome. PURPOSE: This phase II trial is studying giving treosulfan together with fludarabine to see how well it works in treating patients who are undergoing a donor stem cell transplant for acute myeloid leukemia, acute lymphoblastic leukemia, or myelodysplastic syndrome.

Clinical Trial Conditions for Treosulfan

Condition Name

Condition Name for
Intervention	Trials
Myelodysplastic Syndrome	8
Chronic Myelomonocytic Leukemia	5
Acute Myeloid Leukemia	5
Multiple Myeloma	4

Condition MeSH

Condition MeSH for
Intervention	Trials
Myelodysplastic Syndromes	16
Leukemia	16
Preleukemia	14
Leukemia, Myeloid, Acute	12

Clinical Trial Locations for Treosulfan

Trials by Country

Trials by Country for
Location	Trials
United States	54
Germany	21
Italy	12
Poland	6
Canada	6

Trials by US State

Trials by US State for
Location	Trials
Washington	10
Oregon	6
Colorado	5
Wisconsin	4
Tennessee	3

Clinical Trial Progress for Treosulfan

Clinical Trial Phase

Clinical Trial Phase for
Clinical Trial Phase	Trials
Phase 3	7
Phase 2/Phase 3	1
Phase 2	27

Clinical Trial Status

Clinical Trial Status for
Clinical Trial Phase	Trials
Completed	14
Unknown status	11
Not yet recruiting	6

Clinical Trial Sponsors for Treosulfan

Sponsor Name

Sponsor Name for
Sponsor	Trials
medac GmbH	14
National Cancer Institute (NCI)	8
Fred Hutchinson Cancer Research Center	8

Sponsor Type

Sponsor Type for
Sponsor	Trials
Other	59
Industry	26
NIH	12